The Medicines Co.
(NASDAQ : MDCO)

( )
MDCO PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
CTLTCatalent, Inc. -0.05%85.512.1%$238.66m
SAVACassava Sciences, Inc. 10.18%10.820.0%$188.62m
JAZZJazz Pharmaceuticals Plc 0.00%138.982.4%$167.77m
HZNPHorizon Therapeutics Plc 0.00%78.845.8%$157.84m
CORTCorcept Therapeutics, Inc. 0.00%17.995.5%$131.66m
VRXValeant Pharmaceuticals International, Inc. 0.06%16.5314.1%$97.26m
BHCBausch Health Cos., Inc. 0.06%16.530.0%$65.61m
AMRNAmarin Corp. Plc 0.00%4.011.5%$58.04m
MYOKMyoKardia, Inc. 0.00%126.351.8%$57.07m
ARGXargenx SE -2.40%243.030.0%$53.64m
SAGESAGE Therapeutics, Inc. 0.00%59.888.6%$46.83m
GWPHGW Pharmaceuticals Plc 0.00%100.066.2%$42.93m
AXSMAxsome Therapeutics, Inc. 0.00%78.791.9%$38.86m
MRNSMarinus Pharmaceuticals, Inc. 0.00%3.211.9%$37.52m
PRGOPerrigo Co. Plc 0.00%45.926.8%$35.91m

Company Profile

The Medicines Company is focused on advancing the treatment of critical care patients through the delivery of innovative, cost-effective medicines to the worldwide hospital marketplace. The Company markets Angiomax(R) (bivalirudin) in the United States and other countries for use in patients undergoing coronary angioplasty, and Cleviprex(R) (clevidipine butyrate) injectable emulsion in the United States for the reduction of blood pressure when oral therapy is not feasible or not desirable. The Company also has two products in late stage development: cangrelor, an investigational antiplatelet agent, and oritavancin, a semi-synthetic lipoglycopeptide antibiotic. The Company's pipeline also includes a serine protease inhibitor, CU2010, in early-stage development.